Synthego, the genome engineering company, has collaborated with The Krogan Lab, a world-renowned scientific research unit at the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), to deliver multiple CRISPR-based engineered cell lines to accelerate the study of potential treatment targets for SARS-CoV-2, the novel coronavirus that causes COVID-19 disease. In a study published in Science, the consortium of researchers used Synthego-engineered cells targeting more than 300 genes that the virus interacts with inside a human cell.
Click here for original story, Synthego’s CRISPR platform enables faster ID of potential Coronavirus treatment
Source: Phys.org